Actively Recruiting

Phase 2
Age: 65Years - 80Years
All Genders
Healthy Volunteers
NCT07275424

Study of Healthy Aging and Physical Function With Elamipretide

Led by David Marcinek · Updated on 2025-12-10

30

Participants Needed

1

Research Sites

20 weeks

Total Duration

On this page

Sponsors

D

David Marcinek

Lead Sponsor

S

Stealth BioTherapeutics Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study will utilize a daily dose of elamipetide for 4 weeks and will screen a sufficient number of subjects for 30 subjects to enroll in the study. The planned duration of the study includes baseline measurement, followed by 4 weeks intervention period, a midpoint (2week ±3days) check-in phone interview, and post intervention visits that mirror the baseline visits. After the last injection, subjects will enter the 2-week follow-up period, concluded by the end-of-study contact.

CONDITIONS

Official Title

Study of Healthy Aging and Physical Function With Elamipretide

Who Can Participate

Age: 65Years - 80Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 65 to 80 years
  • Lower mitochondrial function with VO2peak ≤ 37.3 ml/kg/min for men or ≤ 25.7 ml/kg/min for women
  • Ambulatory and able to perform daily activities without assistance
  • Sufficient venous access for blood draws
  • Willing and able to self-administer injections or have a caregiver who can
  • Speak and read English
  • No established daily exercise routine or physical hobby and agree not to start during the study
  • Willing to avoid certain medications during the study including anti-seizure drugs, muscle mass or energy supplements, muscle relaxants, systemic steroids, immunosuppressives, and high-dose opioids
  • No known allergies or adverse reactions to Fexofenadine
  • Provide informed consent documentation
Not Eligible

You will not qualify if you...

  • Significant diseases or conditions that increase risk or affect study participation or results
  • Severe kidney disease (eGFR <30 mL/min) or liver disease with elevated liver enzymes (>2x normal)
  • History of rhabdomyolysis
  • Hospitalization within 3 months for major atherosclerotic events or major medical conditions
  • Current enrollment in another investigational drug or device study or incompatible medical research
  • Participation in a clinical study with an investigational product within 30 days prior to screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Washington

Seattle, Washington, United States, 98109

Actively Recruiting

Loading map...

Research Team

S

Sophia Liu, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here